A large international study suggests that a subset of people with Type 2 diabetes carry genetic variants that blunt the effectiveness of widely used GLP-1–based drugs, despite unexpectedly elevated levels of the hormone in their bodies. GLP-1 receptor agonists are now used by more than a quarter of people with Type 2 diabetes, and their […]